Funder
National Key Research and Development Program of China
Publisher
Springer Science and Business Media LLC
Reference5 articles.
1. Tan AJ, Mo DC, Wu K et al (2023) Nephrotoxicity of immune checkpoint inhibitor combination therapy in patients with advanced renal cell carcinoma: a meta-analysis. World J Urol. https://doi.org/10.1007/s00345-023-04407-x
2. Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA (editors). Cochrane handbook for systematic reviews of interventions version 6.3 (updated February 2022). Cochrane, 2022. Available from www.training.cochrane.org/handbook
3. Doi SAR, Barendregt JJ, Khan S et al (2015) Advances in the meta-analysis of heterogeneous clinical trials i: the inverse variance heterogeneity model. Contemp Clin Trials 45:130–138. https://doi.org/10.1016/j.cct.2015.05.009
4. Nolla K, Benjamin DJ, Cella D (2023) Patient-reported outcomes in metastatic renal cell carcinoma trials using combinations versus sunitinib as first-line treatment. Nat Rev Urol. https://doi.org/10.1038/s41585-023-00747-w
5. Bedke J, Rini BI, Plimack ER et al (2022) Health-related quality of life analysis from KEYNOTE-426: pembrolizumab plus axitinib versus sunitinib for advanced renal cell carcinoma. Eur Urol 82:427–439. https://doi.org/10.1016/j.eururo.2022.06.009
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献